Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD) - LARVOL DELTA

Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: Phase 3 COMMAND-3 results (VHC 2014) - Abstract #O213; P3, N=602; COMMAND-3 (NCT01492426); Sponsor: BMS; “In GT1b patients, 75% and 73% of DCV + P/R and TVR + P/R recipients, respectively, achieved eRVR and qualified for 24 weeks of therapy. In GT1b patients, SVR12 rates for DCV + P/R and TVR + P/R were 85% (228/268) and 81% (109/134); the difference was 4.3% [95% CI   3.3%, 11.9%], demonstrating non-inferiority...” 

P3 data • Hepatitis C Virus

Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: The Phase III ATTAIN study (VHC 2014) - Abstract #O212; P3, N=763; ATTAIN (NCT01485991); “SVR12 rates for SMV/PR were non-inferior to TVR/PR in the overall population (53.6% versus 54.7%) as well as in partial- (69.7% versus 68.5%) and null-respond- ers (43.6% versus 46.2%), respectively. Similar SVR12 rates were observed in GT1 subtypes (GT1a/other: 40.2% versus 38.4% and GT1b: 63.7% versus 66.8%, for SMV/ PR and TVR/PR, respectively)....The efficacy of SMV/PR in prior non- responders was non-inferior to TVR/PR. SVR12 rates were similar with SMV/PR and TVR/PR across various sub- groups.”   

P3 data • Hepatitis C Virus